A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients with Relapsed Epothelial Ovarian Cancer

  • Poole, Christopher (Principal Investigator)

Project Details

Short titleA Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients with Relapsed Epothelial Ovarian Cancer
StatusFinished
Effective start/end date1/09/0231/08/05

Funding

  • OSI PHARMACEUTICALS INC